ONWARD Medical reports Q3 2026 revenue of EUR 2.5M
It sold or supplied 88 ARC-EX systems, up 120% year over year, and held EUR 73.4M in cash. Empower BP has 31 participants enrolled.
See the latest news and media coverage for ONWARD. We track all announcements, press releases, and industry mentions in real time, all in one place.
Medical technology company developing spinal cord stimulation therapies
onwd.comLast updated
In short: ONWARD began subacute ARC-IM implants as ARC-EX sales rose and its Empower BP pivotal study advanced.
It sold or supplied 88 ARC-EX systems, up 120% year over year, and held EUR 73.4M in cash. Empower BP has 31 participants enrolled.
ARC-EX unit sales rose 430% year over year, and the company raised EUR 40.6M in equity plus up to EUR 50M in BlackRock debt financing.
ARCEX Systems reached over 100 clinics in the US and Europe, the first Empower BP patient was implanted, and cash runway extends into Q1 2028.
Revenue rose from €1.7M in 2024 as ARCEX sold 117 systems to over 80 US clinics, ending the year with €68.1M net cash.
ONWARD Medical N.V. (ONWD) reported first-half 2026 results, highlighting strong growth in ARC-EX System sales, continued progress across its investigational ARC-IM and ARC-BCI platforms, and...
EINDHOVEN, the Netherlands, Nov. 03, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to...
“In 2025, we established a US commercial organization that drove rapid adoption of our groundbreaking ARC-EX System in US rehabilitation clinics. The FDA 510(k) for...
(ABM FN-Dow Jones) Onward Medical has raised more than 50 million euros through a capital increase. The medtech company announced this on Friday morning. Via a...
Track ONWARD and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to ONWARD and other trending companies.